SC
SRNE

Sophrosyne Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Sophrosyne Capital’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-38,900
Closed -$316K – 92
2013
Q4 		$316K Buy
+38,900
New +$342K 0.28% 44

Other funds holding SRNE

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
B
Baird Milwaukee, Wisconsin $9.78B AUM 11.39% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sophrosyne Capital's SRNE Position: Q1 2014 in Review

Sophrosyne Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2014, closing a stake of 38,900 shares — an estimated $316K sold.

Sophrosyne Capital first reported a position in SRNE in Q4 2013 and held it in 1 quarter. The position peaked at $316K in Q4 2013. 30 funds tracked by Wall St. Rank hold SRNE as of Q1 2014.

  • Sophrosyne Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 38,900 Sorrento Therapeutics, Inc. shares in Q1 2014, an estimated $316K.
  • Sophrosyne Capital first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 1 quarter.
  • Sophrosyne Capital's Sorrento Therapeutics, Inc. position peaked at $316K in Q4 2013.
  • 30 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2014.

Based on Sophrosyne Capital's 13F filing for Q1 2014, filed 14 May 2014.